FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to polypeptides having hydrolysable covalent bonds with therapeutic agents for drug delivery. The invention also refers to pharmaceutical compositions which contain the compounds according to the invention, to using them in methods of treating cancer.
EFFECT: polypeptide conjugates can be used as vectors for a therapeutic agent transport through the blood-brain barrier (BBB) and for delivery into specific types of cells, such as the ovaries, liver, lungs or kidneys.
6 cl, 16 dwg, 8 tbl, 6 ex
Title | Year | Author | Number |
---|---|---|---|
INTENSIFICATION OF ACTION OF ANTICANCER AGENTS | 2006 |
|
RU2422143C2 |
APROTININ POLYPEPTIDES FOR TRANSPORT OF COMPOUND THROUGH BLOOD-BRAIN BARRIER | 2010 |
|
RU2611193C2 |
POLYPEPTIDE CAPABLE OF OVERCOMING HEMATOENCEPHALIC BARRIER, AND CONJUGATE THEREOF | 2005 |
|
RU2408605C2 |
COMPOSITION BASED ON HYDROPHOBIC AGENTS AND METHOD FOR PREPARING IT (VERSIONS) | 2009 |
|
RU2518240C2 |
NOVEL PEPTIDES | 1995 |
|
RU2162855C2 |
CALICHEAMICIN DERIVATIVE-CARRIER CONJUGATES | 2011 |
|
RU2602878C2 |
CONJUGATES "CALIHEAMICIN DERIVATIVE-CARRIER" | 2003 |
|
RU2422157C2 |
CALICHEAMICIN DERIVATIVE-CARRIER CONJUGATES | 2016 |
|
RU2678818C2 |
ANTI-PTK7 ANTIBODY-DRUG CONJUGATES | 2015 |
|
RU2708075C2 |
ANTI-5T4 ANTIBODIES AND USE THEREOF | 2007 |
|
RU2487889C2 |
Authors
Dates
2014-10-20—Published
2009-10-15—Filed